BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript

BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript

Seeking Alpha • 2 hours ago

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

PALO ALTO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on Attruby's commercial progress.

GlobeNewsWire • 6 hours ago

BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to a loss of $1.31 per share a year ago.

Zacks Investment Research • an hour ago

BridgeBio to Participate in March Investor Conferences

PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences:

GlobeNewsWire • Feb 23, 2026

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026.

GlobeNewsWire • Feb 17, 2026

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on February 12, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 34 new employees in restricted stock units for an aggregate of 76,701 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on February 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

GlobeNewsWire • Feb 17, 2026

BridgeBio Unveils Positive Results For Its Most 'Hotly Debated' Phase 3 Drug

BridgeBio unveiled promising results Thursday for its "hotly debated" final-phase asset: a potential treatment for achondroplasia.

Investors Business Daily • Feb 12, 2026

BridgeBio Pharma shares rise on ‘compelling' Phase 3 trial results for achondroplasia drug

BridgeBio Pharma (NASDAQ:BBIO) saw its shares rise more than 5% to about $77 on Thursday after reporting positive Phase 3 topline results for oral infigratinib in achondroplasia, with Jefferies analysts describing the data as “compelling.” Achondroplasia is the most common form of dwarfism, a genetic condition that affects bone growth and results in short stature and disproportionate limb development.

Proactive Investors • Feb 12, 2026

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p

GlobeNewsWire • Feb 12, 2026

BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript

BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript

Seeking Alpha • Feb 12, 2026